TACE With Thermosensitive Nanogel Versus Embosphere for HCC

Exclusion Criteria

• •1. The target lesion has been embolized before or require combined with other treatment(s);
• •2. Diffuse or with extrahepatic metastasis;
• •3. Coagulation dysfunction (PT prolonged beyond the upper limit of normal for 3 seconds);
• •4. Severe renal dysfunctions (creatinine clearance rate \<30 ml/min);
• •5. Severe liver dysfunctions (alanine aminotransferase or aspartate aminotransferase exceeding the upper limit of normal by 5 times);
• •6. Main portal vein was completely occluded and no collateral blood supply was established;
• •7. With uncorrectable arteriovenous fistula or portal vein fistula;
• •8. Severe cachexia or hepatic encephalopathy;
• •9. With active infection;
• •10. Significant reductions in white blood cells or platelets (white blood cells\<3.0x109/L, platelets\<50x109/L) that cannot be corrected;
• •11. Pregnant or lactating women;
• •12. Difficulty in selective catheterization;
• •13. With the severe risk of non-target embolization;
• •14. Severely allergic to contrast agents or the embolic materials;
• •15. Participating in ongoing trial;
• •16. Unsuitable judged by the investigator.